Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression–free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

Recent studies suggest CD133, a surface protein widely used for isolation of colon cancer stem cells, to be associated with tumor angiogenesis and recurrence. We hypothesized that gene expression levels and germline variations in CD133 will predict clinical outcome in patients with mCRC, treated in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Pohl, Alexandra, El-Khoueiry, Anthony, Yang, Dongyun, Zhang, Wu, Lurje, Georg, Ning, Yan, Winder, Thomas, Hu-Lieskoven, Siwen, Iqbal, Sima, Danenberg, Kathleen D., Kahn, Michael, Teo, Jia-Ling, Shriki, Jabi, Stebbing, Justin, Lenz, Heinz-Josef
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3326190/
https://ncbi.nlm.nih.gov/pubmed/22231565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/tpj.2011.61
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares